237 Results for "

Integrin alpha

" in MedChemExpress (MCE) Product Catalog:
Products (237)

237 Results for "Integrin alpha" in MCE Product Catalog:

78
78 Publications Verification
Art. -Nr.: HY-16141
CAS. Nr.: 188968-51-6
Synonyms: EMD 121974
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
loading...
    loading...
78
78 Publications Verification
Art. -Nr.: HY-16143
CAS. Nr.: 199807-35-7
Synonyms: EMD 121974 TFA
Cilengitide TFA (EMD 121974 TFA) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide TFA inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide TFA inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide TFA can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
loading...
    loading...
12
12 Cited Publications
Art. -Nr.: HY-13535A
CAS. Nr.: 904763-27-5
Reinheit:  99.04%
Synonyms: ATN-161 TFA salt
Target:  

Integrin

Forschungsgebiete:  

Cancer

ATN-161 trifluoroacetate salt is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
loading...
    loading...
12
12 Cited Publications
Art. -Nr.: HY-13535
CAS. Nr.: 262438-43-7
ATN-161 is an antagonist of α5β1 integrin and αvβ3 integrin, as well as an inhibitor of fibrosis, an inhibitor of oxidative stress, a tight junction stabilizer, a mitochondrial integrity protector, an angiogenesis inhibitor and an antiviral agent. ATN-161 inhibits NLRP3, MAPK, and ROS. ATN-161 protects mice from SARS-CoV-2 infection . ATN-161 reduces infarct volume, alleviates edema, decreases immune cell infiltration, reduces the area of choroidal neovascularization lesions, lowers tumor microvessel density and viral load. ATN-161 can be used in research related to ischemic stroke, choroidal neovascularization, breast cancer, coronavirus disease 2019 (COVID-19), and liver metastasis of colorectal cancer .
loading...
    loading...
11
11 Cited Publications
Art. -Nr.: HY-P1740
CAS. Nr.: 114681-65-1
Target:  

Integrin Apoptosis Caspase

Forschungsgebiete:  

Inflammation/Immunology

RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
loading...
    loading...
11
11 Cited Publications
Art. -Nr.: HY-P1740A
Target:  

Integrin Apoptosis

Forschungsgebiete:  

Inflammation/Immunology Cancer

RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .
loading...
    loading...
8
8 Cited Publications
Art. -Nr.: HY-15102
CAS. Nr.: 227963-15-7
Reinheit:  99.50%
Synonyms: L-000845704
Target:  

Integrin

Forschungsgebiete:  

Inflammation/Immunology Cancer

MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively .
loading...
    loading...
6
6 Cited Publications
Art. -Nr.: HY-14951
CAS. Nr.: 402567-16-2
Reinheit:  99.75%
Synonyms: SB 683699
Target:  

Integrin

Forschungsgebiete:  

Neurological Disease

Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .
loading...
    loading...
6
6 Cited Publications
Art. -Nr.: HY-15770
CAS. Nr.: 232271-19-1
Reinheit:  98.06%
Target:  

Integrin

Forschungsgebiete:  

Inflammation/Immunology

TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-14571
CAS. Nr.: 289483-69-8
Reinheit:  99.06%
Synonyms: ER68203-00
Forschungsgebiete:  

Infection Metabolic Disease Cancer

E7820 (ER68203-00), an orally active aromatic sulfonamide derivative, is a molecular glue that induces the targeted degradation of splicing factor RBM39 by recruiting the E3 ubiquitin ligase CUL4-RBX1-DDB1-DCAF15 (CRL4 DCAF15). E7820 is an angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. E7820 inhibits rat aorta angiogenesis with an IC50 of 0.11 μg/ml. E7820 modulates α-1, α-2, α-3, and α-5 integrin mRNA expression. E7820 can be used for the study of acute myeloid leukemia (AML) .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-108831
CAS. Nr.: 189261-10-7
Reinheit:  99.10%

Target:  

Integrin

Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
loading...
    loading...
5
5 Cited Publications
Art. -Nr.: HY-108831A
CAS. Nr.: 189261-10-7
Reinheit:  98.72%
Synonyms: AN100226; BG00002

Target:  

Integrin

Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-P9911
CAS. Nr.: 943609-66-3
Synonyms: Anti-Human lymphocyte α4β7 Integrin, Humanized Antibody; LDP-02; MLN-002

Target:  

Integrin

Forschungsgebiete:  

Inflammation/Immunology Cancer

Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-P9911A
CAS. Nr.: 943609-66-3

Target:  

Integrin

Forschungsgebiete:  

Inflammation/Immunology

Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-P80416
Synonyms: CD49e, FNRA, ITGA5, Integrin alpha-5, CD49 antigen-like family member E, Fibronectin receptor subunit alpha, Integrin alpha-F, VLA-5

Host:  

Rabbit

Application:  

WB, ICC/IF, IHC-P, IP, FC

Reactivity:  

Human, Mouse

loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-P1408
CAS. Nr.: 404882-00-4
Target:  

Integrin VEGFR

Forschungsgebiete:  

Cancer

Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .
loading...
    loading...
4
4 Cited Publications
Art. -Nr.: HY-P1408A
Target:  

Integrin

Forschungsgebiete:  

Cancer

Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate can be isolated from the venom of Vipera lebetina obtusa. Obtustatin triacetate is a potent and selective inhibitor of integrin α1β1 adhesion to type IV collagen. Obtustatin triacetate inhibits angiogenesis and may be used in cancer research .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-70073
CAS. Nr.: 455264-31-0
Synonyms: CT7758
Target:  

Integrin

Forschungsgebiete:  

Inflammation/Immunology

Zaurategrast (CT7758) is a potent and oral-effective α4-integrin inhibitor .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-P1868
CAS. Nr.: 134580-64-6
Synonyms: DGEA peptide
Target:  

Integrin

Forschungsgebiete:  

Infection

α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-P1868A
Synonyms: DGEA peptide TFA
Target:  

Integrin

Forschungsgebiete:  

Others

α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
loading...
    loading...